REAL SCIENCE. REAL POSSIBILITIES.A brain-focused peptide tested in human studies of cognition and neurodegenerative conditions, without an established clinical benefit.
Davunetide moved well beyond animal work. Its microtubule and tau rationale led to intranasal trials in mild cognitive impairment, schizophrenia and progressive supranuclear palsy—making the negative clinical findings central to the story.
These cards show what NAP / Davunetide is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
A key part of the research story is supporting microtubules — tiny internal structures that help nerve cells keep their shape and transport materials.
Preclinical work supports interactions with microtubule-related processes, but a mechanism does not guarantee slower neurological decline.
Progressive supranuclear palsy provided a direct clinical test because abnormal tau biology is central to the disease.
Despite that rationale, 30 mg twice-daily intranasal treatment for 52 weeks did not improve either primary clinical endpoint.
Earlier studies explored attention, working memory and functional brain measures.
Small exploratory findings appeared in some analyses, but no robust, replicated cognitive treatment effect was established.
Davunetide demonstrates how a promising neuroprotective mechanism can be examined in a large, international trial.
The PSP result was neutral, while nasal adverse effects supplied practical route-specific safety information.
Davunetide reached meaningful human development. Earlier cognition signals and extensive microtubule research must now be read alongside the negative 52-week PSP result.
Eight-amino-acid NAP sequence
→Tau and cytoskeletal neuroprotection rationale
→MCI, schizophrenia and 313-person PSP study
→No slowing of PSP on either primary endpoint
Davunetide progressed from ADNP-fragment biology into international human trials. Its programme contains both exploratory cognition findings and one decisive negative result in PSP.
Preclinical research links NAP with microtubule-related processes and neuronal resilience.
Smaller 12-week trials explored attention, working memory and functional brain outcomes.
A 313-person trial used 30 mg intranasally twice daily for 52 weeks.
The PSP trial did not improve disease severity or activities of daily living.
313 participants with progressive supranuclear palsy across 48 centres
63 people with schizophrenia receiving stable antipsychotic treatment
144 adults with amnestic mild cognitive impairment
Controlled intranasal studies included a 313-person phase 2/3 trial and smaller cognition programmes.
Davunetide did not improve progression in PSP; broader cognitive efficacy remains unconfirmed.
Trial safety data exist, including route-specific nasal events, but unsupervised products and long-term use outside trials are not characterised.
Cell and animal work supports microtubule, tau and neuroprotection hypotheses.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Multiple monitored intranasal trials
Pivotal PSP result negative; cognition uncertain
No approved neurological treatment role
A measured biological response can be valuable evidence without establishing a self-administered protocol or a durable treatment benefit.
Memory, tau and neuroprotection goals—mapped against real intranasal human trials, uncertain cognition signals and a negative pivotal PSP result.
Community goals · human trial exposure · efficacy boundaryDavunetide is explored around memory, neuroprotection and tau-related disease. Unlike many community peptides it has substantial human trial data, but the largest and most clinically decisive study did not show benefit in PSP.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
Interest often draws on earlier mild-cognitive-impairment and schizophrenia studies.
Twelve-week trials generated exploratory signals but no robust, replicated overall cognitive benefit.
ADNP-fragment research supports neuronal and microtubule hypotheses.
A human-tested idea that remains clinically unproven.
Davunetide is often discussed as if target relevance alone predicts disease modification.
The 52-week phase 2/3 PSP trial was negative on both primary outcomes.
Microtubule stability and reduced tau phosphorylation motivated the trial.
The direct human test outweighs mechanism-only optimism for PSP.
The nasal route is seen as practical and potentially CNS-directed.
Trials demonstrate that intranasal administration was feasible, not that retail sprays reproduce exposure or efficacy.
Nose-to-brain concepts offer a rationale but do not guarantee delivery.
A studied route with concentration, device and product-quality dependence.
Some users extrapolate the 52-week PSP design toward maintenance or prevention.
The long trial did not slow PSP and was not conducted in healthy users.
Chronic animal protection cannot define preventive human use.
Trial duration should not be mistaken for a successful maintenance schedule.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toNAP / Davunetide, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
These are separate intranasal trial arms—not a titration ladder. The highest and longest protocol failed to slow PSP.
Randomized 12-week research arm
Higher 12-week research arm
52-week pivotal protocol
Both primary endpoints were neutral
Epistaxis, rhinorrhoea and nasal discomfort were more frequent with davunetide in the PSP trial. Device and formulation still matter.
The source documents the published phase 2/3 exposure and its negative efficacy result. It is not a dosing recommendation.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
Davunetide has published intranasal human protocols, but no approved neurological dose and no evidence-led self-use schedule.
Adults with progressive supranuclear palsy
Published study structure, shown as data — not a personal dosing schedule.
This high-dose trial was negative on both primary efficacy endpoints; it is not a target for community dosing.
Adults in monitored cognition programmes
Published study structure, shown as data — not a personal dosing schedule.
These were randomized research arms, not a validated nootropic titration or maintenance plan.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Davunetide + Diagnosis-specific therapy and rehabilitation
Davunetide + Targeted cognitive strategies
Davunetide + Experimental cognitive peptides
The programme reached phase 2/3, but davunetide did not slow PSP and has no approved cognitive indication.
Rehabilitation can have independent value. Semax and Pinealon are community pairings without controlled combination evidence.
The peptide was studied as a disease-modifying candidate within structured clinical care.
Davunetide did not improve PSP progression and should not replace symptom management, rehabilitation or multidisciplinary support.A pharmacological hypothesis and structured compensatory training address different parts of cognitive difficulty.
No controlled trial establishes additional benefit from the combination; rehabilitation should stand on its own evidence.Community stacks combine microtubule, neurotrophic and neural-ageing narratives.
No human combination study supports synergy; overlapping CNS uncertainty makes effects and adverse events harder to attribute.PSP, MCI, medication effects and healthy-user goals are fundamentally different contexts.
A combination does not reverse the pivotal PSP trial outcome.
Bleeding, discomfort, sleep or behavioural changes become harder to attribute in a stack.
Randomized intranasal studies provide route, exposure and adverse-event information beyond a preclinical peptide profile.
Davunetide did not improve disease severity or activities of daily living after 52 weeks.
Exploratory cognition signals have not produced an approved treatment, while retail formulation and long-term self-use are unvalidated.
The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Epistaxis, rhinorrhoea and nasal discomfort were more frequent with davunetide in the PSP trial.
New falls, gaze difficulty, swallowing change, focal weakness, confusion or rapid cognitive decline needs clinical assessment.
Device delivery, concentration, purity and combinations with other CNS-active compounds change uncertainty.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
Davunetide / NAP is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
